Connect to Us LinkedIn Youtube RSS


Aruba, October 17, 2013 - Cancer costs countries in the European Union 126bn euro (£107bn) a year, according to the first EU-wide analysis of the economic impact of the disease. The charity Cancer Research UK said it was a "huge burden".

The figures, published in the Lancet Oncology, included the cost of drugs and health care as well as earnings lost through sickness or families providing care. Lung cancer was the most costly form of the disease. The team from the University of Oxford and King's College London analysed data from each of the 27 nations in the EU in 2009. They showed the total cost was 126bn euro and of that 51bn (£43bn) euro was down to healthcare costs including doctors' time and drug costs.

Lost productivity, because of work missed through sickness or dying young, cost 52bn (£44bn) euro while the cost to families of providing care was put at 23bn (£19.5bn) euro. Overall, richer countries, such as Germany and Luxembourg, spent more on cancer treatment per person than eastern European countries such as Bulgaria and Lithuania.

Lung cancer accounted for more than a tenth of all cancer costs in Europe. The deadly cancer tends to affect people at an earlier age than other cancers so the lost productivity through early deaths is a major factor.

Other issuesHowever, the overall economic burden is behind the costs of dementia and cardiovascular disease. An EU-wide study, by the same research group, showed cardiovascular diseases, including high blood pressure and stroke, cost 169bn euro (£144bn) a year while dementia cost 189bn euro (£169bn) in just 15 countries in Western Europe.

Dementia has very high costs associated with long-term care while cardiovascular diseases include such a wide range of conditions it affects many more people than cancer.

One of the researchers, Dr Ramon Luengo-Fernandez, from the Health Economics Research Centre at the University of Oxford, said: "By estimating the economic burden of several diseases it will be possible to help allocate public research funding towards the diseases with the highest burden and highest expected returns for that investment."

Read more/ source: